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RESOURCE USE AND COST DETERMINANTS FOR PATIENTS WITH CROHN’S
DISEASE IN A POLISH TERTIARY HOSPITAL
Petryszyn P, Dudkowiak R, Witczak I, Paradowski L
Wroclaw Medical University, Wroclaw, Poland
OBJECTIVES: To evaluate resource use and cost determinants associated with hospi-
talization of Crohn’s disease patients. METHODS: All patients hospitalized at our
institution from 01.01.2010 to 30.11.2011 were analyzed. We extracted all inpatient
records whose hospital discharge abstracts included ICD-10 code K50 consistent with
the diagnosis of Crohn’s disease. Statistical analysis was performed using the chi-
square test. RESULTS: Of 4028 all hospital admissions 315 belonged to Crohn’s dis-
ease. There were 150 females and 145 males, mean patient age was 37.8 years. 52
(16.5%) patients were hospitalized more than once therefore the total number of pa-
tients hospitalized was 220. The mean length of stay was 5.1 days. There were 42
hospitalizations in order to administer anti-TNF drug; these were excluded from fur-
ther analysis. The distribution of resource use was as follows: plain abdominal radio-
graph (6.2% of hospitalizations), small bowel pass through (5.9%), chest x-ray (36.3%),
abdominal ultrasound (76.6%), CT (13.9%), CT enteroclysis (25.3%), MRI (4.8%), upper
gastrointestinal endoscopy (52.7%), colonoscopy (55.7%). The drug usewas as follows:
sulfasalazine (22.3%),mesalamine (55.7%), azathioprine (26.7%), steroids (15.8%), anti-
biotics (23.8%). 11cases required totalparenteralnutrition.The lengthof stay, resource
anddruguseweredependentondiseaseactivity. 65.5%patientswithCRP10.0mg/dl
were hospitalized for not more than 5 days. Patients in whom antibiotics were used
accounted for 23.8% of cases and 40% of costs. CONCLUSIONS: The structure of
inpatient treatment costs for CD has been demonstrated for a Polish hospital.
Direct medical costs are in relation with disease activity.
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PROTON PUMP INHIBITOR (PPI) PRESCRIBING PATTERNS, PPI COSTS, AND
RESOURCE UTILIZATION IN A NATIONALLY REPRESENTATIVE SAMPLE OF
PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)
Solem CT1, Mody RR2, Stephens JM1, Macahilig C3, Yu S2, Gao X1
1Pharmerit International, Bethesda, MD, USA, 2Takeda Pharmaceuticals International, Inc.,
Deerfield, IL, USA, 3Medical Data Analytucs, Parsippany, NJ, USA
OBJECTIVES: PPIs are commonly used for GERD treatment, a condition character-
ized byheartburn and acid reflux symptoms. This study aimed to describe prescrib-
ing patterns, healthcare resource utilization, and PPI costs in a nationally repre-
sentative sample of GERD patients. METHODS: A nationally representative chart
review and patient/physician survey was conducted in GERD patients currently
taking a prescription PPI (esomeprazole-ESO, lansoprazole-LAN, omeprazole-OME,
dexlansoprazole-DEX, rabeprazole-RAB, pantoprazole-PAN). Physicians reported
their prescribing patterns in the past 6 months. Patient prescription information
and rationale for prescribing were also collected from charts. Annual PPI cost was
calculated by multiplying Red Book AWP by reported dose per day x 365.25.
RESULTS: 252 physicians [74 gastroenterologists (GEs), 178 primary care physicians
(PCP)] and 501 patients (94 ESO, 74 LAN, 94 OME, 94 DEX, 75 PAN, 70 RAB) were
included in the study. Patients were 51 years old on average, 37% male, with 16%
erosive versus 56% symptomatic GERD (28% undocumented). Physicians reported
most frequently prescribing OME (26.4% of their patients), with GEs more likely to
prescribe DEX (PCP 11%/GE 19%, p0.001) and RAB (PCP 9%/GE 13%, p0.01) and
PCPsmore likely to prescribeH2 blockers (PCP 12%/GE 7%). DEXwas the only PPI not
prescribed twice daily. 8%(PAN)-20%(OME) of other PPIs were used twice daily.
Moreover, all DEX patients were prescribed labeled doses, in contrast with other
PPIs prescribed at doses higher than labeled [6%(ESO)-37%(OME)]. Average annual
PPI costs ranged from $1600(DEX)-$3000(RAB), p0.001. There were no significant
differences in GERD-related hospitalizations, emergency room visits, or physician
visits across PPIs. CONCLUSIONS: Prescribing patterns varied greatly across PPIs.
While all included PPIs are labeled for once daily use, DEXwas observed as the only
PPI prescribed in full accord with the labeled doses and not prescribed twice daily
in our cohort. It also incurred lower medication costs compared to other PPIs.
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PREDICTORS OF NONPERSISTENCE AND NONADHERENCE WITH ORAL 5-
AMINOSALICYLIC ACID THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
Yen L1, Wu J2, Hodgkins P1, Nichol MB2
1Shire Development, LLC, Wayne, PA, USA, 2University of Southern California, Los Angeles, CA,
USA
OBJECTIVES: Assess risk factors associated with nonpersistence/nonadherence to
oral 5-aminosalicylic acid (5-ASA) medications in ulcerative colitis (UC) patients.
METHODS: IMS LifeLink™ Health Plan claims data 2007-2011 were analyzed to
identify patients 18 years with 1 UC diagnosis (ICD-9-CM: 556.x) and had 1
prescription for 5-ASA [balsalazide disodium, mesalamine delayed release, Multi-
Matrix System mesalamine (MMX), sulfasalazine] during the study period. 5-ASA
Medications nonpersistence/nonadherence following 12 months initial prescrip-
tion fill (indexmedication) were evaluated. Nonpersistence with indexmedication
was assessed for discontinuation (gap 60 days). Switch was identified if patients
changed to another product after discontinuing the index medication. Nonadher-
ence was determined bymedication possession ratio (MPR)0.8 for indexmedica-
tion, and proportion of days covered (PDC)0.8 for any 5-ASA. Coxmodel assessed
relative hazards associated with discontinuation. Logistic regression investigated
risk factors associated with nonadherence (PDC0.8). RESULTS: A total of 7608
patientsmet selection criteria. Themedian days to discontinuation differed signif-
icantly across index medications (range, 97 [sulfasalazine] to 175 days [MMX],
P0.0001). Patients on MMX were less likely to discontinue (75.3% vs 80.8%,
P0.0001), or switch (9.9% vs. 12%, P0.01), and more likely to adhere to their
medications (MPR0.8; 24.1% vs. 18.0%, P0.0001) than those on other medica-
tions. Major predictors of nonpersistence included index medication vs MMX (bal-
salazide disodium: HR1.18; mesalamine delayed release: HR1.23; sulfasalazine:
HR1.44), preferred provider organization (PPO) vs health maintenance organiza-
tion (HR1.10), and no prior use of immunosuppressive agents (HR1.26). Signifi-
cant variables associated with nonadherence included not switching medication
(OR2.03), residing in South versusMidwest region (OR1.42), never receiving spe-
cialist care (OR1.34), and Medicaid/Medicare versus commercial plan (OR1.44).
CONCLUSIONS: Patients on once-dailyMMXhad the lowest risk of discontinuation
and the highest adherence rate. Multiple factors including not using immunosup-
pressive agents, residing in South region, PPO plan, and non-commercial payer
were associated with nonpersistence/nonadherence with 5-ASAs.
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HOSPITALIZATION BURDEN OF GASTRO-INTESTINAL STROMAL TUMORS
Datar M, Khanna R
University of Mississippi, University, MS, USA
OBJECTIVES:Gastrointestinal Stromal Tumors (GISTs) arising from interstitial cells
of Cajal are known to result in significant healthcare utilization and costs. The
objective of this study was to determine hospitalization burden of GISTs, and as-
sess the factors predicting length of stay (LOS), total costs, and mortality among
individuals with GIST. METHODS: Data from the 2009 Nationwide Inpatient Sam-
ple were analyzed for the purpose of this study. Inpatient burden among individ-
uals with GIST (cases) were compared to those without any diagnosis of cancer
(controls) (case-control matched in 1:4 ratio). Multiple linear regression analysis
was used to determine the factors predicting LOS and total charges, and logistic
regression was used to determine predictors of mortality. RESULTS: In 2009, there
were a total of 14,562 hospitalizations among individuals with GIST in the United
States. Individualswith GIST had higher income, private insurance, identified from
teaching hospitals, higher LOS, higher total costs and higher number of diagnoses
as compared to controls. Individuals having income of $39,000–$47,999 (-
9,089.22; p0.005), individuals in rural hospitals (-13,443.01; p0.0001), increase
in LOS ($6,069.69; p0.0001) and increase in number of diagnoses ($1,008.35;
p0.03) were associated with higher total charges. Ages 35-49 (1.04; p0.04),
50-65 years (1.23; p0.03), 65-79 years (0.96; p0.03) and increase in number
of diagnoses (0.48; p0.0001) were associated with longer LOS among individu-
als with GIST. Rural hospitals (-1.02; p0.03) and patients who had a routine
discharge (-2.67; p0.0001) were associatedwith shorter LOS. Low income (Odds
Ratio [OR]2.36; p0.015), location of hospital in Midwest (OR2.17; p0.0001) and
increase in number of diagnoses (OR1.14; p0.0001) were associated with higher
odds of mortality among patients with GIST. CONCLUSIONS: The study highlights
the significant inpatient burden associated with GIST. Policy makers and health
care professionals could use these results to make appropriate health care deci-
sions aimed at improving outcomes in individuals with GIST.
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HEALTH CARE INDICATORS TO MEASURE QUALITY OF CARE IN PATIENTS
WITH LIVER DISEASES
Cortesi PA1, Scalone L1, Okolicsanyi S1, Rota M1, Ciaccio A1, Ideo G2, Valsecchi MG1,
Mantovani L3, Cesana G1, Strazzabosco M1
1University of Milano - Bicocca, Monza (MB), Italy, 2Fondazione FADE, Milano, Italy, 3Federico II
University of Naples, Naples , Italy
OBJECTIVES: Liver Diseases (LDs) are prevalent and generate high human and
economic costs to the society. Efficient strategies of diagnosis and treatment are
necessary to improve patients’ health and reduce costs. Our aim was to identify
healthcare quality indicators (HCQIs) to measure quality of care provided to LD
patients.METHODS: This work was conducted using a modified Delphi methodol-
ogy based on a two-stage rating process. We organized 7 expert panels, involving
8-10 hepatologists each. Each panel focused on one/few condition(s): hepatitis B,
hepatitis C, cirrhosis, hepatocellular carcinoma, autoimmune hepatopathies and
cholangiopathies, metabolic hepatopathies, liver transplant. For each condition a
preliminary set of HCQIs was identified and discussed by the panel, according to
evidence and experience. Then, each panelmember performed a first independent
rating of all HCQIs using the RAND 9-point agreement scale (RAS; 1totally dis-
agree to 9totally agree). Median scores of each HCQI were calculated and then
used to rate again the HCQIs in the light of these results. After this second rating, a
disagreement index (DI) was calculated to identify and accept (if DI1) indicators
with median RAS7. The final set of HCQIs was selected. RESULTS: The final list
included 8 valid HCQIs for hepatitis B, 7 for hepatitis C, 4 for compensated cirrhosis,
8 for decompensated cirrhosis, 10 for hepatocellular carcinoma, 12 for autoim-
mune hepatopathies and cholangiopathies, 11 for metabolic hepatopathies and 15
for liver transplant. Health-Related Quality-of-Life was included as a further HCQI
in all conditions. CONCLUSIONS:We identified and proposed a set of indicators as a
tool to assess the quality of care provided to patients affected with LDs. After a vali-
dation process, which is being performed, their use could help clinicians and budget
holders in understanding and improving the efficiency of the health care provided.
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A RISK-BENEFIT ANALYSIS OF NATALIZUMAB ACROSS PML RISK SUB-GROUPS
IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
Walker AR1, Deniz B2, Alexopoulos ST1, Arnold R2, Bates D3
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OBJECTIVES: Progressive multifocal leukoencephalopathy (PML) is an infrequent
but serious adverse event associatedwith natalizumab in the treatment of patients
with relapsing-remittingmultiple sclerosis (RRMS). The objective is to evaluate the
risks and benefits of natalizumab treatment across three PML risk sub-groups
against comparator agent interferon- and no treatment. METHODS: The risk-
benefit analysis was conducted using an adaptation of the original natalizumab
model submitted to the National Institute for Health and Clinical Excellence that
simulates natural disease progression and potential treatment impact on out-
comes. A PML risk stratification component was incorporated to define PML risk by
anti-JC virus (JCV) antibody status, previous immunosuppressant (IS) history, and
duration of exposure to natalizumab therapy. A disutility score was applied to PML
and post-PML states, as well as disease states defined by EDSS scores. RESULTS:
Over a 20-year time horizon, treating anti-JCV antibody negative patients with
natalizumab resulted in a total of 6.49 quality-adjusted-life-years (QALYs) per pa-
tient. Treatment with natalizumab in the anti-JCV antibody positive sub-groups,
with and without previous IS history resulted in 6.27 and 6.43 QALYs per patient,
respectively. Interferon- treatment resulted in 6.05 QALYs per patient across all
PML risk groups, whereas no treatment led to 5.82 QALYs per patient. In the highest
risk group (anti-JCV antibody positive with prior IS use), utility decrement due to
PMLwas small compared to the lowest risk anti-JCV antibody negative group (0.22),
and overall QALYs were higher than interferon- and no treatment. When consid-
ering the overall RRMS patient population, the risk of PML associated with natali-
zumab had to be more than 10.43 times higher in order to result in equivalent
QALYs with interferon-. CONCLUSIONS: The risk of PML associated with natali-
zumab treatment is offset by the benefit of natalizumab across all patient groups
compared to interferon- and no treatment.
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DOPAMINE AGONISTS AND DYSKINESIA IN ADVANCED PARKINSON’S
DISEASE: A NETWORK META-ANALYSIS OF ROTIGOTINE, PRAMIPEXOLE AND
ROPINIROLE AS ADJUNCT THERAPY TO LEVODOPA
Senior E1, Dedeken P1, Naci H2
1UCB Pharma, Brussels, Belgium, 2Mapi Values, London, UK
OBJECTIVES: The development of dyskinesia in Parkinson’s disease (PD) patients
may be associated with pulsatile stimulation of dopamine receptors, especially
when using short-acting dopaminergic agents such as levodopa. Adjunctive ther-
apy to levodopa with dopamine agonists may increase the risk of dyskinesia. This
study quantitatively assessed the short-term incidence of dyskinesia in patients
with advanced PDwhen treatedwith rotigotine transdermal patch (RTG) compared
with ropinirole (ROP) and pramipexole (PPX) immediate-release (IR) and extended-
release (ER). METHODS: A systematic review of randomized controlled compara-
tive trials of RTG, ROP, PPX and placebo (PBO) on a background of levodopa therapy
in advanced PD patients was performed, followed by a network meta-analysis.
Trials published up to September 2011 were included. Incidence of dyskinesia was
assigned as reported in each study. Study-level relative treatment effects were
combined using both random-effect (base case) and fixed-effectmodels (sensitivity
analysis) within a Bayesian framework using Markov Chain Monte Carlo methods
in WinBUGS. RESULTS: Sisteen trials and 4446 patients were incorporated in the
meta-analysis, which included 20 direct pair-wise comparisons. Patient character-
istics were similar in terms of mean age at baseline, disease duration and severity
(UPDRS III); however, average levodopa dosage differed across studies (range 272.9-
843.4 mg/day). Under the base case assumption, odds of dyskinesia occurrence
were comparable across dopamine agonists; odds numerically favored RTG over
ROP-IR (OR: 0.70 [95% CI: 0.31, 1.59]), ROP-ER (0.33 [0.09, 1.15]) and PPX-IR (0.86 [0.49,
1.58]), but not PPX-ER (1.02 [0.42, 2.43]). The sensitivity analysis suggested that
patients receiving RTGwere estimated to experience fewer dyskinesias than those
receiving ROP-ER (0.32 [0.11, 0.88]). CONCLUSIONS: This meta-analysis suggests
that in levodopa-treated patientswith advanced PD, dopamine agonists were com-
parable in terms of short-term odds of experiencing dyskinesia, with a numerical
trend favoring RTG over ROP-ER. Further large-scale, confirmatory randomized
clinical trials are required.
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INDIRECT TREATMENT COMPARISON (ITC) ANALYSIS OF THERAPIES THAT ARE
OFTEN CONSIDERED FOR TREATMENT-EXPERIENCED PATIENTS WITH
RELAPSING-REMITTING MULTIPLE SCLEROSIS
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OBJECTIVES: Relapsing-remitting multiple sclerosis (RRMS) is the most common
form of MS and is characterised by inflammatory episodes in the brain followed by
periods of remission. Damage caused by relapses accumulates over time andmany
patients will develop some form of permanent disability after 10 years. Natali-
zumab 300mg, fingolimod 0.5mg and INF-1a 44mcg are typically considered for
treatment-experienced patients with RRMS. This meta-analysis aimed to assess
the efficacy of natalizumab versus other potential treatments for RRMS.METHODS:
Electronic searches of Medline, Embase and the Cochrane library were undertaken
to identify potential studies conducted in adults with RRMS treated with natali-
zumab, fingolimod or INF-1a. Direct meta-analysis was conducted in STATA ver-
sion 12 using the metan package. Indirect comparisons between treatments via
common comparators were made using the Bucher method. RESULTS: Out of 2512
records obtained from systematic searches, forty studies were included in the final
data set. Analysis of evidence suggested that patients treated with natalizumab
were twice as likely to remain free from disease activity (ie free from both clinical
and radiological activity) at 24months comparedwith fingolimod (OR2.05, 95%CI:
1.127, 3.735). Progression of disability (i.e. increase in EDSS score) was lower in
patients treated with natalizumab compared with fingolimod (mean difference in
EDSS score change -0.69, 95% CI: -0.882,-0.498). Patients treatedwith natalizumab
had a 50% lower chance of relapse per year comparedwith INF-1a (OR0.5, 95%CI:
0.391, 0.640). Likewise, patients receiving fingolimod were less likely to have a
relapse in a year comparedwith INF-1a (OR0.64, 95% CI: 0.477, 0.867). Analysis of
additional outcomes based on limited data, showed directional favour towards
natalizumab compared with fingolimod and INFb-1a without reaching statistical
significance.CONCLUSIONS:Comparedwith fingolimod and IFNb-1a, natalizumab
was shown to be a more effective treatment alternative for RRMS patients in this
analysis.
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TRENDS OF Z-DRUGS PRESCRIPTIONS IN TAIWANESE ADULT POPULATIONS
Yu IW1, Lin HW2, Liao CH1, Chou CH3, Wu MP2
1China Medical University Hospital, Taichung, Taiwan, 2China Medical University, Taichung,
Taiwan, 3Northeastern University, Boston, MA, USA
OBJECTIVES: Those non-benzodiazepine hypnotics (Z-drugs) were introduced for
the short-term management of insomnia due to its advantage of favorable safety
profiles. It is inconclusive about its benefits of long-term use and risks of depen-
dence concerning Z-drugs. This study was to examine the trends of Z-drugs pre-
scriptions stratified by elderly and non-elderly adult populations across times in
Taiwan.METHODS:We conducted a secondary data analysis using 2000 and 2005
Longitudinal Health Insurance Database (2 million random samples). During the
observation period (2003 to 2009), we defined adult outpatient users as those NHI
adult beneficiaries (aged 18 year-old) ever made outpatient visits and Z-drug
users as those ever prescribed with Z-drugs (zolpidem, zopiclone and zaleplon) in
each year. The prescription prevalence rate of Z-drugs, its average number of de-
fined daily dose (DDD) and prescriber specialties were stratified by age (elderly vs.
non-elderly) and gender and compared across years. RESULTS: Among adult out-
patient users, the prescription prevalence rate of Z-drugs was increased from 2003
to 2005, decreased in 2006 but maintained from 2007 to 2009. Female and non-
elderly patients were predominant (all about 61%) across years. The average DDD
within one year were increased over 7-year period (exception in 2006) and that
among elderly users was always higher than non-elderly users. There were up to
8.3% of Z-drug users prescribed with over 365 DDD yearly (9.0% in elderly group).
While 36% were prescribed by more than two specialties, the top 4 prescriber
specialties were general/family medicine, internal medicine, psychiatry and neu-
rology, regardless of age groups and years. CONCLUSIONS: Except in 2006, the
Z-drugs prescription was gradually increased but maintained from 2003 to 2009 in
Taiwan. Those common prescribers of Z-drugs should be warrant about its long-
term uses for whole year, especially among the elderly.
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BUDGET IMPACT ANALYSIS OF FINGOLIMOD FOR THE TREATMENT OF
MULTIPLE SCLEROSIS IN COLOMBIA
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BACKGROUND: Multiple sclerosis (MS) is a neurodegenerative disease associated
with long-term disability and significant social economic impact. Available first-
line diseasemodifying treatments for MS (interferons and glatiramer acetate) have
moderate efficacy and must be administered in daily or weekly injections. The
introduction of fingolimod, a newmolecule which superior efficacy in reducing MS
relapses compared to interferon-beta 1a im justifies a budget impact analysis from
the Colombian health system perspective. OBJECTIVES: To develop a budget im-
pact analysis, for years 2012 to 2016, of the introduction of fingolimod in the Co-
lombian health system, for the treatment of remitting relapsing multiple sclerosis
(RRMS). METHODS: Using the perspective of the Colombian health system, we
designed a budget impact model to compare costs of illness with and without the
introduction of fingolimod for patients with RRMS. Clinical data and prevalence
were obtained from published literature, costs were collected from local sources. A
Monte Carlo simulationwas performed as part of the sensitivity analysis. Exchange
rate usedwas 1.786 Colombian pesos per US dollar (Jun 2011). No discount rate was
used. RESULTS: Total annual net costs (from 2012 to 2016) for the scenario without
fingolimod were, in million USD, $11.44, $12.16, $12.75, $13.47, and $14.18. In the
fingolimod scenario net costs were: $11.46, $12.23, $12.83, $13.59 and $14.41. On the
other hand, fingolimod was associated with 91 relapses averted in this five year
period. Monte Carlo simulation did not show significant differences in costs be-
tween both scenarios. CONCLUSIONS: Under these assumptions, the introduction
of fingolimod in the Colombian health care system does not imply a significant
budget impact but represents an important reduction in the number of relapses.
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BUDGET IMPACT ANALYSIS OF ANTIEPILEPTIC DRUGS IN THE TREATMENT OF
LENNOX-GASTAUT SYNDROME
Skornicki M, Clements KM, O’Sullivan AK
OptumInsight, Medford, MA, USA
OBJECTIVES: Lennox-Gastaut syndrome (LGS) is a debilitating form of epilepsy
characterized by developmental disorders and high frequency of drop attacks that
are often refractory to antiepileptic drug (AED) therapy. Clobazamwas approved by
the FDA in October 2011 for adjunctive treatment of seizures associated with LGS.
Wedeveloped amodel to compare the budget impact of adding clobazam to anAED
portfolio containing topiramate, lamotrigine, and rufinamide in a hypothetical
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